Abstract

BackgroundTyrosine kinase inhibitors (TKIs) have revolutionised the treatment of Chronic Myeloid Leukaemia (CML). Adherence to this chronic treatment is essential to attain the therapeutic objectives expected.PurposeTo identify patients on TKIs...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call